Danaher (NYSE:DHR) Upgraded by Piper Sandler to Hold Rating

Danaher (NYSE:DHR) was upgraded by research analysts at Piper Sandler to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

Several other equities research analysts also recently weighed in on DHR. HSBC lowered their price target on Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Royal Bank Of Canada began coverage on Danaher in a report on Thursday, May 14th. They issued an “outperform” rating and a $200.00 price target for the company. Barclays lowered their price target on Danaher from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Rothschild & Co Redburn set a $205.00 price target on Danaher in a report on Friday, April 17th. Finally, Argus lowered their price target on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a report on Friday, April 24th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $233.61.

Danaher Price Performance

DHR opened at $180.65 on Thursday. The business’s 50-day moving average is $181.15 and its two-hundred day moving average is $204.96. Danaher has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.52. The firm has a market capitalization of $127.86 billion, a PE ratio of 34.94, a price-to-earnings-growth ratio of 2.45 and a beta of 0.81.

Danaher (NYSE:DHR) last posted its earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.12. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The company had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the previous year, the firm earned $1.88 earnings per share. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. Research analysts anticipate that Danaher will post 8.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Danaher

A number of institutional investors and hedge funds have recently modified their holdings of the company. Brandywine Financial Group acquired a new stake in shares of Danaher during the first quarter worth about $8,698,000. Dakota Community Bank & Trust NA lifted its holdings in shares of Danaher by 41.0% during the first quarter. Dakota Community Bank & Trust NA now owns 265 shares of the conglomerate’s stock worth $50,000 after purchasing an additional 77 shares during the period. FAS Wealth Partners Inc. lifted its holdings in shares of Danaher by 10.2% during the first quarter. FAS Wealth Partners Inc. now owns 13,649 shares of the conglomerate’s stock worth $2,588,000 after purchasing an additional 1,262 shares during the period. Pine Valley Investments Ltd Liability Co lifted its holdings in shares of Danaher by 4.4% during the first quarter. Pine Valley Investments Ltd Liability Co now owns 13,289 shares of the conglomerate’s stock worth $2,520,000 after purchasing an additional 558 shares during the period. Finally, Evansbrook LLC lifted its holdings in shares of Danaher by 11.7% during the first quarter. Evansbrook LLC now owns 1,375 shares of the conglomerate’s stock worth $261,000 after purchasing an additional 144 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.